Monthly research recap
LSD research: February 2026
What February 2026's 11 new studies found, synthesized from the papers below. All LSD research →
The synthesis
Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for LSD, lysergic acid diethylamide, lysergide, then ranked by relevance.
Research on LSD in February 2026 shows short-term mood improvements from microdosing in depression (Phase 2a trial) and significant antidepressant and anxiolytic effects in a large compassionate-use cohort, but also identifies potential cardiac risks from chronic use via 5-HT2B receptor activation. Results are consistent across clinical and real-world settings, but the evidence is limited by small samples, open-label designs, and lack of long-term safety data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial 2026 | Phase 2a trial | Supports | Microdosed LSD (8 μg) showed short-term mood improvements with no tolerance or sensitization, warranting further controlled trials. | |
| Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland. 2026 | observational (compassionate-use cohort) | 115 | Supports | LSD-assisted psychotherapy (100 μg) significantly reduced depressive and anxiety symptoms with mild, transient adverse events. |
| Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease. 2026 | systematic review | Opposes | LSD has high affinity for 5-HT2B receptors and promotes signaling linked to valvular heart disease in in vitro and structural studies, suggesting potential cardiac risk with chronic use. | |
| Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature 2026 | systematic review | Mixed | LSD and other psychedelics enhanced emotional empathy but impaired reaction time, attention, and inhibition dose-dependently, with mixed effects on memory and cognitive flexibility. | |
| Psychedelic Symphonies: Investigating LSD and Music-Induced Brain Activity Using fMRI 2026 | RCT (two double-blind, cross-over studies) | 51 | Supports | LSD (100 μg) altered brain connectivity in resting-state networks and limbic regions, with music enhancing these effects, suggesting neural mechanisms for therapeutic outcomes. |
Points of agreement
- LSD shows acute and short-term positive effects on mood and anxiety in clinical and real-world settings.
- LSD alters brain connectivity and emotional processing, potentially underlying therapeutic benefits.
- Adverse effects are generally mild and transient in controlled settings.
Conflicts
- The systematic review on cognitive effects reports dose-dependent impairments in reaction time and attention, while the clinical studies focus on mood improvements without reporting cognitive deficits.
- Cardiac risk evidence from in vitro studies contrasts with the lack of serious cardiac adverse events in the compassionate-use cohort.
Gaps
- No long-term follow-up data on durability of mood improvements or cardiac safety.
- No placebo-controlled trials for LSD-assisted psychotherapy in the provided studies.
- Limited data on optimal dosing, frequency, and patient selection for LSD therapy.
- No studies on LSD interactions with common medications (e.g., antidepressants) in humans.
- No research on LSD effects in diverse populations or real-world unsupervised use.